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This paper will focus on knowledge related to brain metastases from ovarian carcinoma. So far, less than 600 cases were
documented in the literature with an incidence among ovarian carcinoma patients ranging from 0.29% to 11.6%. The ovarian
carcinoma was usually an advanced-stage epithelial serous carcinoma, and the median interval between diagnosis of ovarian
carcinoma and brain metastases was 2 years. Most often, brain metastases, aﬀected the cerebrum, were multiple and part of a
disseminated disease. Treatment of brain metastasis has evolved over the years from whole brain radiotherapy (WBRT) only
to multimodal therapy including surgical resection or stereotactic radiosurgery followed by WBRT and/or chemotherapy. The
median survival after diagnosis of brain metastases was 6 months; nevertheless, a signiﬁcantly better survival was achieved with
multimodal therapy compared to WBRT only. It is suggested that brain imaging studies should be included in the followup of
patients after treatment for ovarian carcinoma.
1.Introduction
The brain, along with the bone, liver, and lung, is one of the
most common sites of metastasis with about 170,000 new
cases of brain metastases diagnosed each year in the USA, a
ﬁgurewhichis10-fold higherthanthatofpatients diagnosed
with primary brain malignancies [1–3]. Common sources
of brain metastases are lung, breast, renal and colorectal
carcinoma, and malignant melanoma, and it has been
estimated that up to 40% of patients with these cancers may
develop brain metastasis in the course of their disease [1, 3–
5]. Nevertheless, brain metastases from cancers of the female
genital tract, apart from choriocarcinoma, are rare and usu-
ally found in association with widely disseminated systemic
disease. The primary mechanism of spread from the genital
tracttothebrainisbyhematogenousdisseminationoftumor
cells to the lungs and then to the brain via the pulmonary
vasculature [6]. Ogawa et al. [6] reviewed 2,729 women
withprimarygenitaltractmalignanciestreatedduring1985–
2006 and identiﬁed 18 women (0.7%) with brain metastases.
The incidence of brain metastases from ovarian carcinoma
(7/335, 2.1%) was higher than those from uterine corpus
carcinoma (4/556, 0.7%), uterine cervix carcinoma (7/1716,
0.4%),andotherfemalegenitaltractmalignanciescombined
(vagina, vulva, and fallopian tube carcinoma) (0/122, 0%).
In USA, epithelial ovarian carcinoma accounts for 3%
of all cancers in women and is the ninth most common
cancer (after breast, lung, colorectal, uterine corpus, thyroid,
non-Hodgkin lymphoma, melanoma, and renal carcinoma)
in women, with 21,990 estimated new cases in 2011 [7].
Ovarian carcinoma is responsible for 6% of all cancer deaths
in women and is the ﬁfth most common cause of death
from cancer (after lung, breast, colorectal, and pancreas
carcinoma) in women, with 15,460 estimated deaths from
this disease in 2011 [7]. Ovarian carcinoma is the ﬁrst
most common cause of death from female genital tract
malignancies in the western world and the second most
common cause of death (after uterine cervix carcinoma)
from female genital tract malignancies worldwide [8–10].
In 2007, the incidence (new cases/100,000 women/year)
of ovarian carcinoma and the death rate (deaths/100,000
women/year) from ovarian carcinoma in USA were 12.5 and2 ISRN Oncology
8.2, respectively [11]. The National Cancer Institute (NCI)
has estimated that 1.4% (1/70) of women born today in USA
will develop epithelial ovarian carcinoma at some time in
their lives [11]. In 2008, worldwide, 225,000 women were
newlydiagnosedwithovariancarcinoma(3.7%ofallcancers
in women), and 140,000 women died of this disease (4.2%
of all deaths from cancer in women). Worldwide, ovarian
carcinoma is the seventh most common cancer in women
(after breast, colorectal, uterine cervix, lung, gastric, and
uterine corpus carcinoma) and the seventh most common
cause of death from cancer in women (after breast, lung,
colorectal, uterine cervix, gastric, and liver carcinoma). The
estimated incidence and death rate of ovarian carcinoma in
2008 worldwide have been 6.3 and 3.8, respectively [10].
Brain metastasis from ovarian carcinoma is uncommon,
with less than 600 cases documented to date in the literature.
Because of the rarity of brain metastasis from ovarian
carcinoma, most reports include singular cases or series of
patients in which patient accrual occurred over prolonged
periods of time during which treatment approaches and
modalities changed. This paper will focus on the following
topics related to brain metastases from ovarian carcinoma:
incidence of brain metastasis from ovarian carcinoma, char-
acteristics and treatment of the primary ovarian carcinoma,
interval between diagnosis of ovarian carcinoma and brain
metastasis, type and site of brain metastasis, symptoms
and signs of brain metastasis, CA-125 at diagnosis of
brain metastases, prognostic indices for patients with brain
metastases, treatment of brain metastases, and survival after
diagnosis of brain metastases.
2. Incidence
Since the advent of chemotherapy some ﬁfty years ago, an
increase in the incidence of brain metastasis from various
cancers has been noticed compared to the prechemotherapy
era. This has been explained by the longer survival of cancer
patients due to more aggressive treatments of the primary
tumor, rising incidence of lung carcinoma and malignant
melanoma, and ability to detect small tumors in the brain
due to improvement in imaging techniques (e.g., computer-
ized tomography [CT], magnetic resonance imaging [MRI],
and positron emission tomography [PET]) [1, 3].
With the advent of platinum-based chemotherapy as
standard treatment for epithelial ovarian carcinoma some
three decades ago, a prolongation of survival of ovarian
carcinoma patients compared to the preplatinum-based
chemotherapy era has been achieved. Though more than
75% of patients with epithelial ovarian carcinoma are
diagnosed with an advanced-stage disease (FIGO stage
III/IV), a long-term survival is achieved in 15% to 30%
of these patients by debulking (cytoreductive) surgery
followed by platinum-based chemotherapy. Epithelial
ovarian carcinoma is a disease that remains locoregionally
conﬁned until late in its natural history, and hematogenous
metastases are rare at presentation (16%), with the most
common sites of metastatic spread being the pleural cavity
(33%), liver (26%), and lung (3%) [12]. Prolongation of
survival of epithelial ovarian carcinoma patients achieved
due to platinum-containing chemotherapy has been claimed
to be the main reason for the rising incidence of brain
metastasis from ovarian carcinoma. It has been claimed that
while chemotherapy for ovarian carcinoma is eﬀective in
controlling tumor cell deposits in the abdominal cavity and
elsewhere except the central nervous system (CNS), it is
much less eﬀective in controlling tumor cell deposits in the
CNS since the chemotherapy molecules have diﬃculties in
crossing the blood-brain barrier (BBB) [1, 3, 4]. The BBB
is a continuous endothelium with tight junctions and little
pinocytic vesicle activity that lines the microvasculature of
the brain and, thus, limits the entry of circulating macro-
molecules into the brain parenchyma [4]. Nonetheless, the
BBB does not prevent the invasion of the brain parenchyma
by circulating metastatic cells [1, 4]. Fidler [4] and Langley
and Fidler [1] showed that metastatic cells in the brain
parenchyma exploit homeostatic mechanisms to their own
advantage and, thus, have suggested that future therapy of
brain metastases should be directed against both the tumor
cells (“seed”) and the brain microenvironment (“soil”).
Since in the prechemotherapy era the survival of patients
with advanced-stage epithelial ovarian carcinoma was short,
and there was not enough time for brain metastasis to
develop, data with respect to brain metastasis from ovarian
carcinoma in the prechemotherapy era are quite scarce and
mostly based on autopsy series. Mayer et al. [13]s u r v e y e d
576 autopsies of ovarian carcinoma patients collected from
ﬁve large autopsy series published in the literature before
1978 [14–18] and found only ﬁve (0.86%) patients having
brain metastases from ovarian carcinoma. The same authors
[13] reviewed 1,441 patients with brain metastases collected
from nine clinical and autopsy series published in the
literature before 1978 and revealed that ovarian carcinoma
was the source of brain metastases in 14 (0.97%) patients.
These authors [13] also reviewed 97 patients with lep-
tomeningeal metastasis collected from three series published
in the literature before 1978 and observed that the ovary
was not the source of leptomeningeal metastasis in any of
the patients. LeChevalier et al. [19] reviewed 120 patients
with brain metastases from various primary tumors and
found that ovarian carcinoma was the source of brain
metastases in 4 patients (6.5%) only. Larson et al. [20]
surveyed 4,456 patients with epithelial ovarian carcinoma
treated at The University of Texas M. D. Anderson Hospital
and Tumor Institute during 1944–1984 and revealed 13
(0.29%) patients with brain metastases; remarkably, no
patients were identiﬁed as having brain metastases before
1968. Kolomainen et al. [21] surveyed 3,690 patients with
epithelial ovarian carcinoma treated at the Royal Marsden
Hospital during 1980–2000 and found 18 (0.5%) patients
with brain metastasis. An increase in the incidence of brain
metastases from epithelial ovarian carcinoma over time
was observed; the incidence during 1980–1984 was 0.2%,
1985–1989—0%, 1990–1994—0.3%, and 1995–1999—1.3%
(P<0.001) [21]. Chen et al. [22] checked their hospital’s
computer database of ovarian carcinoma patients and no
patient with brain metastases was found before 2000, but
10 (1.9%) of 539 ovarian carcinoma patients treated during
2000–2007hadbrainmetastases.Dauplatetal.[23]r eviewedISRN Oncology 3
the records of 255 patients with epithelial ovarian carcinoma
treated at the University of California Los Angeles (UCLA)
Medical Center during 1973–1983 and observed that brain
metastases developed in ﬁve patients (1.96%) while pleural
metastases developed in 63 patients (24.7%), liver metastases
in 24 patients (9.4%), lung metastases in 18 patients (7.1%),
distant lymph node (beyond pelvic and para-aortic chains)
metastases in 18 patients (7.1%), skin metastases in 9
patients (3.5%), pericardial metastases in 6 patients (2.4%),
and bone metastases in four patients (1.6%). Overall, 97
(38%) of the 255 patients had developed extraperitoneal
or parenchymal liver metastases; the 5 patients with brain
metastases accounted for 5.2% of these 97 patients [23].
Thirty-eight clinical series of patients with CNS metasta-
sis from ovarian carcinoma, totaling 521 patients, have been
published in the literature from 1978 until to date [6, 13, 20–
22, 24–56]( Table 1). In 29 series in which the number
of ovarian carcinoma patients is available, 34,728 ovarian
carcinoma patients were surveyed, and 413 (1.19%) of them
were found to have CNS metastases [6, 20–22, 24–27, 29–
31, 33–35, 37, 39–43, 45–49, 52–55]( Table 1). The incidence
of CNS metastasis among ovarian carcinoma patients was
<1% in 5 series [20, 21, 24, 47, 48], 1–1.9% in 10 series
[22, 27, 33, 39, 41–43, 49, 54, 55], 2–2.9% in 8 series [6, 29,
31, 34, 35, 45, 46, 53], 3–3.9% in 3 series [37, 40, 52], and
≥4% in 3 series [25, 26, 30]( Table 1). The claim made by
some authors that the incidence of brain metastases among
ovarian carcinoma patients is rising rapidly and approaching
12% [30] is not supported by most series published in the
literature showing that the incidence of brain metastasis
among ovarian carcinoma patients is within the range of
1–3% (Table 1).
3.PrimaryOvarianCarcinoma
Someauthorsquestionedwhetherpatientswithbrainmetas-
tases from ovarian carcinoma tend to be younger at the
time of diagnosis of ovarian carcinoma than the general
ovarian carcinoma population [13, 27]. Nonetheless, it has
been observed that the median age at the time of diagnosis of
ovarian carcinoma of patients with brain metastasis is very
close to the median age at the time of diagnosis of ovarian
carcinomainthegeneralovariancarcinomapopulation[37].
In the series of patients with brain metastases from ovarian
carcinoma published in the literature, the median age of the
patientsatthetimeofdiagnosisofovariancarcinomaranged
from 44 to 60 years [6, 13, 20–22, 24–56].
The vast majority of the patients (>80%) with brain
metastases from ovarian carcinoma had at the time of diag-
nosis of the primary disease an advanced-stage (stage III/IV)
serous epithelial ovarian carcinoma [57]. The commonest
histologic grade was 3 (poorly diﬀerentiated) [57]. Initial
treatment of the ovarian carcinoma consisted generally of
debulking (cytoreductive) surgery including total abdominal
hysterectomy, bilateral salpingo-oophorectomy, and omen-
tectomy followed by adjuvant chemotherapy. The accrual
of patients in the series published in the literature oc-
curred over prolonged periods of time during which
chemotherapy regimens for ovarian carcinoma evolved
considerably during the years from melphalan, through
cyclophosphamide, through combination of doxorubicin
and cyclophosphamide, through combination of cisplatin,
doxorubicin and cyclophosphamide (PAC) to present day
platinum- and taxane-based combination chemotherapy.
Chemotherapy employed for the primary ovarian carcinoma
in the series and singular cases reported in the literature
included the following regimens: (1) oral chemotherapy:
melphalan (Alkeran) [13, 27, 47], chlorambucil (Leukeran)
[24],hexamethylmelamine(Altretamine)[13];(2)intraperi-
toneal chemotherapy: thiotepa [24], cytosine arabinoside
[35], carboplatin [58], paclitaxel [58]; (3) intravenous
chemotherapy: cyclophosphamide (Cytoxan, Endoxan) [13,
47], doxorubicin (Adriamycin) [37], cisplatin [24, 45, 58],
paclitaxel (Taxol) [59], doxorubicin and cyclophosphamide
[37], cisplatin and oral chlorambucil [24], cisplatin and oral
hexamethylmelamine [24, 37], cisplatin and cyclophos-
phamide [22, 35, 37, 45, 60, 61], carboplatin and cyclophos-
phamide [62, 63], carboplatin and oral chlorambucil [60],
cisplatin and paclitaxel [43, 47], carboplatin and paclitaxel
[22, 45, 48, 52, 64–67], carboplatin and docetaxel (Taxotere)
[68], cisplatin, doxorubicin and cyclophosphamide [25, 27,
30, 31, 35–37, 39, 45, 47, 50, 58, 69], carboplatin, doxoru-
bicin, and cyclophosphamide [35], cisplatin, paclitaxel and
ifosfamide [52], cisplatin, paclitaxel and anthracycline [52],
cisplatin, doxorubicin, cyclophosphamide and oral hexam-
ethylmelamine [45, 70], “platinum-based chemotherapy”
[38, 43, 44, 51, 55, 71].
A considerable number of patients treated for their
primary ovarian carcinoma with platinum-based adjuvant
chemotherapy were chemotherapy-sensitive and experi-
enced a complete clinical response. Second-look procedure
(laparoscopy/laparotomy) was performed in a portion of
these patients and was reported to be negative in approxi-
matelyhalfofthepatientsinwhomitwasperformed[20,25–
27, 29, 31, 33, 38, 39, 43, 44, 47, 61–63, 65, 69, 72–75].
4.BrainMetastases
4.1. Interval between Diagnosis of Ovarian carcinoma and
Brain Metastasis. The interval between diagnosis of ovarian
carcinoma and brain metastases was available in 31 series
totaling 460 patients [13, 21, 22, 24–28, 30–33, 35–38, 41–
45, 47–56]. The medians of the interval between diagnosis
of ovarian carcinoma and brain metastases ranged from 11
to 46 months with a median of the medians of 24.3 months
(Table 1). Interestingly, brain metastasis was detected at
the time of the diagnosis of ovarian carcinoma in four
patients [30, 33, 43, 47], and brain metastasis was diagnosed
two weeks prior to the diagnosis of ovarian carcinoma in
one patient [51]. Brain metastasis diagnosed simultaneously
with the ovarian carcinoma was documented by Bakar and
Tekk¨ ok[76],andbrainmetastasisdetectedthreemonthsand
two weeks before the diagnosis of ovarian carcinoma was
reported by Izquierdo et al. [74] and Matsunami et al. [77],
respectively.
LeRoux et al. [33] observed that the interval between
diagnosis of ovarian carcinoma and brain metastasis was
ﬁve times shorter in stage III/IV ovarian carcinoma patients4 ISRN Oncology
Table 1: Incidence of CNS metastases among ovarian carcinoma patients, interval between diagnosis of ovarian carcinoma and CNS
metastases, survival after diagnosis of ovarian carcinoma, and survival after diagnosis of CNS metastases.
Author (year) [ref.] Study period Number of
patients with OC
Number of
patients with CNS
metastases (%)
Median Interval
between diagnosis
of OC and CNS
metastases in
months (range)
Median survival
after diagnosis of
OC in months
(range)
Median survival
after diagnosis of
CNS metastases in
months (range)
Mayer et al. (1978)
[13] 1973–1977 NA 6 26 (2–82) 38 (8–85+) 4.5 (2–33+)
Barker et al. (1981)
[24] 1969–1979 430 4 (0.9) 34 (11–72) 37 (13–78) 4 (0.2–8)
Budd et al. (1983)
[25] 1978–1980 42 3 (7.1) 19 (19–20) NA NA
Larson et al. (1986)
[20] 1944–1984 4,456 13 (0.29) NA 26 5
Stein et al. (1986)
[26] 1979–1985 110 5 (4.5) 17 (16–43) 28 (18–43) 2 (1–11)
Dauplat et al. (1987)
[27] 1973–1983 255 5 (1.96) 25 (10–126) 24 (11–135) 1 (1–10)
Ziegler et al. (1987)
[28] 1983–1985 NA 5 11 (11–31) NA 8 (1–9+)
Ross et al. (1988)
[29] 1980–1984 342 7 (2) NA 27 (12–52) 6.5 (2–26)
Hardy and Harvey
(1989) [30] 1981–1984 52 6 (11.6) 28.5 (0–36) 30 (3–126) 4.5 (2–41+)
Piura et al. (1990)
[31] 1961–1988 200 2 (1) 22 (21–23) 41.5 (40–43) 19.5 (19–20)
Plaxe et al. (1990)
[32] NA NA 6 28.5 (2–61) NA 10 (2–24)
LeRoux et al. (1991)
[33] 1980–1989 1,316 14 (1.1) 14.5 (0–72) NA 3 (0.1–36)
Rodriguez et al.
(1992) [34] 1977–1990 795 16 (2) NA NA 9
Bruzzone et al.
(1993) [35] 1981–1989 413 9 (2.2) 19 (3–36) 26 (10–81) 8 (1–45)
Salvati and Cervani
(1994) [36] 1980–1988 NA 4 21 (10–26) NA 28 (17–48)
Geisler and Geisler
(1995) [37] 1979–1992 479 16 (3.3) 19 (2–41) NA 3 (1–24)
Cormio et al. (1995)
[38] 1982–1994 NA 23 35 (5–114) 42 (8–133) 5 (1–24)
Suzuki et al. (1999)
[39] 1982–1998 311 4 (1.3) NA NA NA
Zhao et al. (1999)
[40] 1989–1997 132 4 (3%) NA NA 10 (2–19+)
Kaminsky-Forrett et
al. (2000) [41] 1974–1998 704 8 (1.1) 15 (2–80) NA 3 (1–12)
Sanderson et al.
(2002) [42] 1995–2000 1,222 13 (1.1) 36 (6–60) NA 6 (2–42+)
Anupol et al. (2002)
[43] 1986–2000 1,042 15 (1.4) 22 (0–53) 38 (9–82) 6 (0–49)
Kolomainen et al.
(2002) [21] 1980–2000 3,690 18 (0.5) 46 (12–113) NA 7 (1–41)
Pothuri et al. (2002)
[44] 1989–2001 NA 14 42 (15.6–98.4) NA 18 (0.5–32.8)
Kumar et al. (2003)
[45] 1991–2001 658 18 (2.7) 29 (0–101) 30.5 (5–110) 4 (1–74)ISRN Oncology 5
Table 1: Continued.
Author (year) [ref.] Study period Number of
patients with OC
Number of
patients with
CNS metastases
(%)
Median Interval
between
diagnosis of OC
and CNS
metastases in
months (range)
Median survival
after diagnosis of
OC in months
(range)
Median survival
after diagnosis of
CNS metastases
in months
(range)
Li and Fu (2003)
[46] 1996–2000 478 10 (2.1) NA NA 6.3 (<1–33)
Cohen et al. (2004)
[47] 1975–2001 8,225 72 (0.9) 22 (0–219) 40.5 (95% CI,
21.5–60) 6.3 (95% CI, 5–8)
Tay and Rajesh
(2005) [48] 1993–2003 605 4 (0.66) 16.5 (8–65) NA 19.5
Pectasides et al.
(2005) [49] 1983–2004 1,450 17 (1.17) 15.9 (1.4–70.8) 27.4 (3–71.4) 5.7 (0.2–22.6)
D’Andrea et al.
(2005) [50] 1980–2000 NA 11 21 NA 28
Chen et al. (2005)
[51] 1985–2002 NA 19 25.2 (−0.6–112) NA 16.3 (0.2–111.5)
Kastritis et al.
(2006) [52] 1995–2004 267 8 (3) 17.2 67 (95% CI,
48–85)
22 (95% CI,
12–34)
Kim et al. (2007)
[53] 1996–2005 490 13 (2.7) 28 (13–99) NA 7 (0–30)
Ogawa et al. (2008)
[6] 1985–2006 335 7 (2.1) NA NA 7.3 (0.9–48.2)
Lee et al. (2008)
[54] 1983–2005 1,413 18 (1.3) 28 (8–71) NA 14 (1–63)
Sehouli et al.
(2010) [55] 1981–2008 4,277 74 (1.7) 28.8 (2.6–133.1) 36.2 (95% CI,
33.3–39.1)
6.2 (95% CI,
4.9–7.5)
Chen et al. (2011)
[22] 2000–2007 539 10 (1.9) 24.3 (7–55) NA 3 (0–16)
Cormio et al.
(2011) [56] 1995–2010 NA 20 33 (3–70) NA 17.6 (0–59)
Total 34,728a 521b 413c (1.19) 24.3 (11–46)d 33.3 (24–67)d 6.4 (1–28)d
CNS: central nervous system; OC: ovarian carcinoma; NA: not available.
aThis number represents the total number of patients with ovarian carcinoma in 29 series in which the number of ovarian carcinoma patients is available.
bThis number represents the total number of patients with brain metastases from ovarian carcinoma in all 38 series reviewed.
cThis number represents the total number (percentage) of patients with brain metastases from ovarian carcinoma in 29 series in which the number of ovarian
carcinoma patients is available.
dMedian (range) of the medians. Interval between diagnosis of ovarian carcinoma and brain metastases was available in 31 series totaling 460 patients.
Survival after diagnosis of ovarian carcinoma was available in 16 series totaling 236 patients. Survival after diagnosis of brain metastases was available in 36
series totaling 513 patients.
than in stage I/II ovarian carcinoma patients. Cohen et al.
[47] reported that patients with poorly diﬀerentiated (grade
3) ovarian carcinoma had a median interval of 1.5 years
between diagnosis of ovarian carcinoma and brain metas-
tases, as opposed to a median interval of 4.73 years in
patients with well and moderately diﬀerentiated (grades
1 and 2) ovarian carcinomas (P = 0.03). It has, thus,
been accepted that advanced-stage and poorly diﬀerentiated
ovarian carcinoma place the patient at greater risk for
brain metastasis. The vast majority of the patients in the
reported series had advanced-stage (stage III/IV) ovarian
carcinoma and was given intravenous platinum-based com-
bination chemotherapy as postoperative ﬁrst-line adjuvant
chemotherapy.Althoughmostpatientsinitiallyrespondedto
the chemotherapy, including complete responses, the tumor
usually recurred within two years of cytoreductive surgery
and chemotherapy. The relatively wide median interval (two
years) between the diagnosis of ovarian carcinoma and
diagnosisofbrainmetastasisstrengthenstheassumptionthat
prolongation of life of ovarian carcinoma patients due to
the control of intra-abdominal disease by platinum-based
chemotherapy provides suﬃcient time for brain metastasis
to develop and become apparent.
4.2. Type and Site of Brain Metastasis. Type of central
nervous system (CNS) metastasis with respect to whether
the metastasis is conﬁned to the CNS only or is part of a
disseminated disease was available in 35 series totaling 504
patients [13, 20–22, 24, 26–38, 40–56]; 236 (46.8%) patients
had isolated CNS metastasis (metastasis conﬁned to the CNS
only), and 268 (53.2%) patients had CNS metastasis as part
of a disseminated disease that aﬀects also extracranial sites6 ISRN Oncology
(Table 2). Among patients with concomitant extracranial
metastatic disease at diagnosis of brain metastasis, the most
common sites of extracranial recurrence were the peri-
toneum (pelvis and/or abdomen), liver, lungs, and lymph
nodes [49]. Amount of CNS metastases with respect to
whether the metastasis is a single (solitary) brain metastases
or multiple brain metastases or leptomeningeal disease was
available in 33 series totaling 489 patients [13, 20–22, 24, 26–
29, 31–34, 36–38, 40–56], 205 (41.9%) patients had a single
(solitary) brain metastases, 269 (55%) patients had multiple
brain metastases, and 15 (3.1%) patients had leptomeningeal
disease (Table 2). Site of metastasis in the CNS was available
in 35 series totaling 504 patients [13, 20–22, 24, 26–38, 40–
56]; the brain parenchyma was the site of metastasis in
489 (97%) patients and the leptomeninges were the site of
metastasisin15(3%)patients.Ofthe489patientswithbrain
parenchyma metastasis, the cerebrum was the site of brain
metastasis in 210 (42.9%) patients, cerebellum in 44 (9%)
patients,cerebrumandcerebellumin11(2.3%)patients,and
site in the brain parenchyma not speciﬁed in 224 (45.8%)
patients (Table 2). Thus, CNS metastasis is located in the
vast majority of the patients (97%) in the brain parenchyma
and is part of a disseminated metastatic disease that aﬀects
also extracranial sites in a slightly more than half of the
patients. Parenchymal brain metastases are usually multiple
and located most often in the cerebrum.
4.3. Symptoms and Signs of Brain Metastases. Common
presenting symptoms and signs of brain metastases from
ovarian carcinoma included headache (∼50% of patients),
confusion, dizziness, decreased mental status, consciousness
disturbance, general weakness, extremity weakness, gait
disturbance, neurological motor deﬁcit, hemiparesis, ataxia,
visual disturbance, papilledema, incontinence, nausea, vom-
iting, speech impairment (Aphasis), parasthesias, syncope,
and seizure [13, 21, 22, 26, 27, 29, 31–33, 36–39, 43–45,
47, 48, 50–52, 54, 55, 57–61, 63, 65, 67–69, 74, 76, 77].
Increased intracranial pressure due to brain edema caused by
thegrowthofmetastasesinthebrainparenchymaisthemain
reason for the headache, nausea, vomiting, and papilledema
[45].
4.4. CA-125 at Diagnosis of Brain Metastases. Serum CA-125
level was found to be increased (>35U/mL) at the time of
diagnosis of brain metastases from ovarian carcinoma in
a subset of patients. Ten of 15 patients (66.6%) with brain
metastasesfromovariancarcinomareportedbyAnupoletal.
[43] had an elevated serum CA-125 level. The median serum
CA-125 level for all patients was 51 (range, 4–1,756)U/mL.
Serum CA-125 level did not predict the length of survival
after brain metastases. Interestingly, 7 of 8 (87%) patients
with isolated brain metastases had elevated serum CA-
125 level compared with only 3 of 7 (42%) patients with
additional extracranial disease [43]. Eight of 10 patients
(80%) with brain metastases documented by Chen et al. [22]
had elevated serum CA-125 level. The median of serum CA-
125 level for all patients was 115 (range, 16–1,214)U/mL.
All seven patients with additional extracranial disease had
elevated serum CA-125 level but only one of three patients
with isolated brain metastases had elevated serum CA-125
level (137U/mL) [22]. Cormio et al. [71] found seven (50%)
of 14 patients in whom serum CA-125 level was examined
at the time of diagnosis of single (solitary) brain metastases
to have elevated serum CA-125 level (median, 178U/mL;
range, 47–897U/mL). Intraperitoneal disease was present
in addition to brain metastases in ﬁve of the seven patients,
whereasserumCA-125elevationwasattributedonlytobrain
metastases in the remaining two patients and these values
returned to normal after surgical resection of the brain
metastases [71]. Seven of 18 patients with brain metastases
documented by Kumar et al. [45] had an elevated serum
CA-125 level (median, 133U/mL; range, 116–800U/mL). Of
15 patients with brain metastases from ovarian carcinoma
treatedbyeither gamma-kniferadiosurgery(GKS)orwhole-
brain radiotherapy (WBRT) studied by Lee at al. [54], only 6
patients had increased CA-125 level (range, 42–3,700U/mL)
at diagnosis of brain metastases. Moreover, CA-125 level did
notpredictthesurvivalrateafterbrainmetastases(P = 0.52)
[54]. In a series of 14 patients with brain metastases from
ovarian carcinoma documented by Pothuri et al. [44],
serum CA-125 levels prior to craniotomy were available in
seven patients, and in ﬁve of these seven patients the levels
were elevated (>35U/mL). Of eight patients with brain
metastases from ovarian carcinoma documented by Kastritis
et al. [52], serum CA-125 level was elevated in two (25%)
patients at the time of diagnosis of brain metastases. In
four patients with brain metastases from ovarian carcinoma
reviewed by Tay and Rajesh [48], CA-125 level at the time
of diagnosis of brain metastases was 8.9, 44, 45.1, and
263U/mL, respectively. Thus, it has been concluded that
serum CA-125 is an unreliable marker for brain metastasis
[48].
4.5. Prognostic Indices. Four prognostic indices have been
designed for patients with brain metastases to guide treat-
ment decisions [2]: (1) the radiation therapy oncology group
(RTOG) recursive partitioning analysis (RPA) divides patients
into three classes. Class I: Karnofsky performance status
(KPS) ≥70, age <65 years, controlled primary tumor and
no systemic disease; Class II: KPS ≥70 and at least one of
these: age ≥65 years, uncontrolled primary tumor, presence
of systemic disease; Class III: KPS <70 [78, 79]. (2) the score
index for radiosurgery (SIR) is the sum of scores (0–2) for
ﬁve prognostic factors: age (≥60, score 0; 51–59, score 1;
≤50, score 2), KPS (≤50, score 0; 60–70, score 1; 80–100,
score 2), systemic disease (progressive, score 0; stable, score
1; complete response or no evidence of disease, score 2),
number of brain metastases (≥3, score 0; 2, score 1; 1, score
2), and volume of largest brain metastases (>13mL, score 0;
5–13mL, score 1; <5mL, score 2) [80]. (3) the basic score
for brain metastases (BSBM) is the sum of scores (0-1) for
three prognostic factors: KPS (50–70, score 0; 80–100, score
1), control of primary tumor (no, score 0; yes, score 1), and
extracranial metastases (yes, score 0; no, score 1) [81]. (4).
The Graded Prognostic Assessment (GPA) is the sum of scores
(0, 0.5, and 1) for four prognostic factors: age (>60, score
0; 50–59, score 0.5; <5 0 ,s c o r e1 ) ,K P S( <70, score 0; 70–
80, score 0.5; 90–100, score 1), number of brain metastasesISRN Oncology 7
Table 2: Type, amount and site of CNS metastases from ovarian carcinoma.
Type and amount of CNS metastases Site of metastases in the brain parenchyma
Number of patients (%) Number of patients
Author (year)
[ref.]
Number of
patients
with CNS
metastases
Isolated
Brain
parenchyma
single (solitary)
Brain
parenchyma
Multiple
LM disease NS Cerebrum Cerebellum
Cerebrum
and
cerebellum
Mayer et al.
(1978) [13] 6 1 (17) 3 (50) 1 (17) 2 (33) 0 3 1 0
Barker et al.
(1981) [24] 4 1 (25) 3 (75) 1 (25) 0 (0) 0 2 2 0
Larson et al.
(1986) [20] 13 5 (38) 5 (38) 7 (54) 1 (8) 12 0 0 0
Stein et al.
(1986) [26] 5 4 (80) 2 (40) 2 (40) 1 (20) 4 0 0 0
Dauplat et al.
(1987) [27] 5 1 (20) 3 (60) 2 (40) 0 (0) 0 4 1 0
Ziegler et al.
(1987) [28] 5 2 (40) 3 (60) 2 (40) 0 (0) 1 1 3 0
Ross et al.
(1988) [29] 7 3 (43) 4 (57) 2 (29) 1 (14) 0 5 1 0
Hardy and
Harvey (1989)
[30]
6 4 (67) NA NA NA 6 0 0 0
Piura et al.
(1990) [31] 2 1 (50) 2 (100) 0 (0) 0 (0) 0 2 0 0
Plaxe et al.
(1990) [32] 6 5 (83) 0 (0) 5 (83) 1 (17) 0 0 4 1
LeRoux et al.
(1991) [33] 14 6 (43) 9 (64) 5 (36) 0 (0) 0 14 0 0
Rodriguez et al.
(1992) [34] 16 11 (69) 5 (31) 10 (63) 1 (6) 15 0 0 0
Bruzzone et al.
(1993) [35] 9 2 (22) NA NA NA 9 0 0 0
Salvati and
Cervoni (1994)
[36]
4 4 (100) 4 (100) 0 (0) (0) 0 4 0 0
Geisler and
Geisler (1995)
[37]
16 8 (50) 8 (50) 8 (50) 0 (0) 0 14 2 0
Cormio et al.
(1995) [38] 23 9 (39) 9 (39) 13 (56) 1 (4) 0 18 4 0
Zhao et al.
(1999) [40] 4 2 (50) 3 (75) 1 (25) 0 (0) 4 0 0 0
Kaminsky-
F o r r e t te ta l .
(2000) [41]
8 1 (13) 6 (75) 2 (25) 0 (0) 0 3 3 2
Sanderson et al.
(2002) [42] 13 5 (38) 4 (31) 8 (62) 1 (8) 0 10 2 0
Anupol et al.
(2002) [43] 15 8 (57) 7 (47) 7 (47) 1 (7) 14 0 0 0
Kolomainen
et al. (2002) [21] 18 8 (44) 9 (50) 9 (50) 0 (0) 18 0 0 0
Pothuri et al.
(2002) [44] 14 7 (50) 12 (86) 2 (14) 0 (0) 0 11 3 0
Kumar et al.
(2003) [45] 18 5 (28) 5 (28) 12 (67) 1 (5) 0 13 2 28 ISRN Oncology
Table 2: Continued.
Type and amount of CNS metastases Site of metastases in the brain parenchyma
Number of patients (%) Number of patients
Author (year)
[ref.]
Number
of patients
with CNS
metastases
Isolated
Brain
parenchyma
single (solitary)
Brain
parenchyma
Multiple
LM disease NS Cerebrum Cerebellum
Cerebrum
and
cerebellum
Li and Fu
(2003) [46] 10 0 (0) 2 (20) 8 (80) 0 (0) 0 10 0 0
Cohen et al.
(2004) [47] 72 31 (43) 25 (35) 44 (61) 3 (4) 0 63 6 0
Tay and Rajesh
(2005) [48] 4 0 (0) 0 (0) 3 (75) 1 (25) 0 3 0 0
Pectasides et
al. (2005) [49] 17 13 (76) 5 (29) 12 (71) 0 (0) 17 0 0 0
D’Andrea et al.
(2005) [50] 11 11 (100) 11 (100) 0 (0) 0 (0) 0 9 2 0
Chen et al.
(2005) [51] 19 9 (47) 7 (37) 12 (63) 0 (0) 19 0 0 0
Kastritis et al.
(2006) [52] 8 2 (25) 4 (50) 4 (50) 0 (0) 0 6 2 0
Kim et al.
(2007) [53] 13 6 (46) 2 (15) 11 (85) 0 (0) 0 6 1 6
Lee et al.
(2008) [54] 15a 10 (67) 5 (33) 10 (67) 0 (0) 15 0 0 0
Sehouli et al.
(2010) [55] 74 39 (52.7) 26 (35) 48 (65) 0 (0) 74 0 0 0
Chen et al.
(2011) [22] 10 3 (30) 1 (10) 9 (90) 0 (0) 10 0 0 0
Cormio et al.
(2011) [56] 20 9 (45) 11 (55) 9 (45) 0 (0) 6 9 5 0
Total 504 236 (46.8) 205 (41.9)b 269 (55)b 15 (3.1)b 224
(45.8)c 210 (42.9)c 44 (9)c 11 (2.3)c
CNS: central nervous system; LM: leptomeningeal; NS: not speciﬁed; NA: not available.
aThere were 18 patients with BM; however, data were analyzed for 15 patients treated with gamma-knife surgery (GKS) or whole brain radiotherapy (WBRT).
bPercentage is calculated for 489 patients in whom amount and distribution of CNS metastases is available.
cPercentage is calculated for 489 patients with parenchymal brain metastases.
(>3, score 0; 2-3, score 0.5; 1, score 1), and extracranial
metastases (present, score 0; none, score 1) [2].
Of these prognostic indices, only the Radiation Therapy
Oncology Group Recursive Partitioning Analysis (RTOG
RPA) classiﬁcation system has been applied by some authors
to patients with brain metastases from ovarian carcinoma.
Chen et al. [51] retrospectively reviewed the medical records
of 19 patients with brain metastases from ovarian carcinoma
treated at the Cleveland Clinic Foundation from 1985 to
2002. Overall, the median survival after diagnosis of brain
metastases was 16.3 (range, 0.2–111.5) months. Retrospec-
tive application of the RTOG RPA classiﬁcation system to
these patients revealed a trend of survival advantage for
patients allocated Class I (24.7 months) compared with
patients allocated Class II (8.9 months) and Class III (2.6
months) (P = 0.31). Moreover, univariate (P = 0.003)
and multivariate (P = 0.03) analyses showed that patients
with a single (solitary) brain metastases had a longer survival
from diagnosis of brain metastases (41.9 months) than those
with multiple brain metastases (6.2 months). Furthermore,
women with controlled primary ovarian carcinoma in the
peritoneal cavity survived signiﬁcantly longer (18.3 months)
than those with an uncontrolled primary ovarian carcinoma
(2.7 months) on univariate (P = 0.006) and multivariate
(P = 0.01) analyses [51]. The authors [51] concluded that in
addition to the RTOG RPA prognostic classiﬁcation system,
the number of metastatic lesions in the brain should also
be taken into consideration in determining the prognosis
for patients with brain metastases from ovarian carcinoma.
Patients with good prognoses, as determined by the RTOG
RPA prognostic classiﬁcation system and number of brain
metastases, will often beneﬁt markedly from aggressive
treatment, especially surgical resection of brain metastases
when appropriate [51].
Kim et al. [53] evaluated prognostic factors in 13 patients
with brain metastases from epithelial ovarian carcinoma.
Overall, the median survival after detection of brain metas-
tases was 7 months. Class of RTOG RPA was a signiﬁcant
predictor for survival by univariate analysis. The median
survival after diagnosis of brain metastases of ﬁve patientsISRN Oncology 9
allocated Class I was 26 months compared to 4 months
of four patients allocated Class II and 4 months of four
patients allocated Class III (univariate analysis, P =0.007).
In multivariate analysis, RTOG RPA class was of borderline
signiﬁcance (P = 0.09) [53]. In another study by Kim et al.
[82] the charts of 25 patients with brain metastases who
had died within 3 months of craniotomy were reviewed.
Onlyoneofthesepatientshadbrainmetastasesfromovarian
carcinoma. In this patient, although the primary ovarian
tumor in the peritoneum was under control at the time of
diagnosis of brain metastases, there was lung metastasis in
addition to brain metastases and the KPS was <70; thus, she
was allocated RTOG RPA Class III. Based on the very short
survival after craniotomy of patients allocated RTOG RPA
Class III, the authors questioned the worth of craniotomy in
the presence of RTOG RPA Class III [82].
5. Treatment of BrainMetastases
Data with respect to treatment modality of brain metastases
was available in 34 series totaling 520 patients [13, 21, 22, 24,
26–39, 41–56]; 182 (35%) patients had WBRT only (median
survival, 4.5 months), 79 (15.2%)—surgery and WBRT
(median survival, 17 months), 70 (13.5%)—WBRT and
chemotherapy (median survival, 9.1 months), 69 (13.3%)—
surgery, WBRT, and chemotherapy (median survival, 20
months), 26 (5%)—surgery only (median survival, 6.7
months), 20 (3.8%)—stereotactic radiosurgery (SRS) or
gamma-knife radiosurgery (GKRS) (median survival, 18
months), 10 (1.9%)—chemotherapy only (median survival,
7.5 months), 7 (1.3%)—surgery and chemotherapy (median
survival not available), and 57 (11%)—no treatment
(steroids only) (median survival, 1.4 months). Thus, therapy
of brain metastases with combination of surgery, WBRT and
chemotherapy, or combination of surgery and WBRT or
SRS/GKRS yielded better survival results (median survival
of 20, 17, and 18 months, resp.) than therapy of brain
metastases with surgery alone, WBRT alone, chemotherapy
alone, WBRT and chemotherapy, and no treatment (median
survival of 6.7, 4.5, 7.5, 9.1, and 1.4 months, resp.).
Thus, apparently, the best survival after diagnosis of brain
metastases was achieved with multimodal therapy including
surgical resection of the brain metastases followed by WBRT
(±chemotherapy) or with SRS/GKRS.
In the above-mentioned series [13, 21, 22, 24, 26–39,
41–56], nevertheless, patient accrual occurred over pro-
longed periods of time during which treatment approaches
and modalities for brain metastases changed. Traditionally,
patients with isolated (limited to the brain only) and single
(solitary) brain metastases generally would undergo resec-
tion of the brain lesion by craniotomy followed by WBRT.
For patients with multiple brain metastases, with or without
extracranial disease, WBRT with or without chemotherapy
has usually been performed. In series and singular case
reports published in literature before 1997, stereotactic
radiosurgery (SRS) or gamma-knife radriosurgery (GKRS)
was yet not included in the treatment of brain metastases
from ovarian carcinoma. Kawana et al. [83] described in
1977 a patient with isolated multiple brain metastases from
ovarian carcinoma which were successfully treated by a mul-
timodality approach including GKRS. Initially, craniotomy
wasperformedinthispatientwithresectionofrightoccipital
and cerebellar lesions, but a left temporal lesion was inac-
cessible. This was followed by WBRT and chemotherapy and
then GKRS for resection of the remaining tumor in the tem-
poral region. This multimodality approach which included
GKRS has produced complete remission of the multiple
brainmetastasesfor21monthswithgoodqualityoflife[83].
Pothuri et al. [44] reported 14 patients having craniotomy
for brain metastases from ovarian carcinoma during 1989–
2001. In 11 of these 14 patients, craniotomy was followed
by WBRT. In one of the 11 patients, WBRT was followed by
stereotactic radiosurgery (SRS). The authors [44]o b s e r v e da
relatively longer survival achieved with craniotomy followed
by WBRT and, thus, concluded that craniotomy followed
by adjuvant WBRT can provide better control of brain
metastases than WBRT alone. Cormio et al. [71]s u r v e y e d
22 patients who had surgical resection of solitary brain
metastasis from ovarian carcinoma. Following surgery, 17
received WBRT and 5 received systemic chemotherapy. The
median survival after diagnosis of brain metastasis was 16
(range, 4–41) months. In comparison, the median survival
for another 34 patients who were not deemed eligible for
surgical resection was only 4 (range, 1–24) months. The
authors [71] concluded that neurosurgical resection of brain
metastasis from ovarian carcinoma is indicated in solitary
lesions in the absence of systemic disease.
Cohen et al. [47] reviewed 72 patients with brain
metastases from ovarian carcinoma treated during 1975–
2001 and found 69 patients in whom the mode of ther-
apy was available; 8 patients were treated by craniotomy
alone, 12—craniotomy and WBRT, 1—craniotomy and
SRS, 35—WBRT alone, 1—WBRT and SRS, 1—WBRT
and chemotherapy, 3—chemotherapy alone, and 8—no
treatment. The authors [47] showed that the combination
of surgical resection, and WBRT resulted in a longer survival
(median,23.07months)thandidWBRTalone(median,5.33
months) or surgery alone (median, 6.9 months) (P<0.01).
Chen et al. [51] reviewed 19 patients with brain metastases
from ovarian carcinoma treated during 1985–2002 and
revealed that 9 patients were treated by WBRT alone, 6—
WBRT and surgery, 1—surgical resection alone, 2—surgery
and SRS, and 1—SRS and WBRT. Patients who underwent
resection of brain metastases had a longer median survival
(33.7 months) than those who did not undergo surgery
(7.4 months) (P = 0.006) [51]. In a series of 13 patients
with brain metastases from ovarian carcinoma reported by
Kim et al. [53], 12 patients had treatment for their brain
metastases. Of these 12 patients, 1 patient had GKRS only,
1—GKRS, resection of brain lesion and WBRT, 1—GKRS
and WBRT, 1—WBRT, chemotherapy and GKRS, 3—WBRT
and GKRS, 2—WBRT only, and 3—WBRT and chemother-
apy. In 7 patients who received treatment including GKRS,
the median survival after diagnosis of brain metastases was
23 months, while the median survival of the others was 4
months (P = 0.003). Moreover, multivariate analysis showed
that treatment modality (treatment including GKSR versus
treatment not including GKSR) was the only signiﬁcant10 ISRN Oncology
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of borderline signiﬁcance (P = 0.09) [53]. Lee at al. [54]
reviewed 18 patients with brain metastases from ovarian car-
cinoma treated during 1983–2005. Five patients (33.3%) had
extracranial metastases in addition to brain metastases, and
5 patients (33.3%) had single (solitary) brain metastases. In
15 patients, brain metastasis was treated with gamma-knife
radiosurgery (GKRS) (7 patients) or WBRT (8 patients).
Overall, median survival after diagnosis of brain metastasis
was 14 (1–59) months. Nevertheless, patients treated with
GKRS had a longer survival (median, 29 months) than those
treated with WBRT (median, 6 months) (P = 0.0061).
The authors [54] concluded that (1) GKRS seems to be an
eﬀective modality for the control of brain metastases and (2)
GKRS improves the overall survival of patients with brain
metastases from epithelial ovarian carcinoma. Sehouli et al.
[55]reviewed74patientswithbrainmetastasesfromovarian
carcinoma treated during 1981–2008. Eleven patients had
surgery alone for their brain metastases, 20—WBRT alone,
14—surgery and WBRT, 2—surgery and chemotherapy,
6—WBRTand chemotherapy, and 21—surgery, WBRT, and
chemotherapy. Thus, multimodal therapy for brain metas-
tases was applied in 43 (58.1%) of the patients, the most
commonmodalitybeingacombinationofsurgicalresection,
WBRT, and chemotherapy (21 patients, 28.4%). The most
frequently applied monotherapy was WBRT (20 patients,
27%). The authors [55] could not show that the use of
multimodal strategies for brain metastases translate into a
signiﬁcantprolongationofsurvival(HazardRatio,0.57;95%
CI, 0.31–1.05) compared with monotherapy. Chen et al. [22]
reviewed 10 patients with brain metastases from ovarian
carcinoma treated during 2000–2007. Nine of the 10 patients
received treatment for their brain metastases; 3 patients
had WBRT alone, 4—WBRT followed by chemotherapy,
1—surgery followed by WBRT and chemotherapy, and 1—
GKRS followed by chemotherapy. The authors [22]c o n -
cluded that the goal of treatment of brain metastases is the
alleviation of the neurological symptoms and improvement
of the quality of life; nevertheless, they could not make any
conclusion from their data regarding the eﬀect of mode of
therapy on survival.
Cormio et al. [56] investigated in 2011 the changes in
the management and outcome of CNS involvement from
ovarian carcinoma since 1994. They compared the clinical
and pathologic characteristics, treatment, and outcome of
23 patients with brain metastases from epithelial ovarian
carcinoma who were treated during 1982–1994 with those of
20 patients treated during 1995–2010. The main diﬀerence
between the two groups was the therapeutic approach to
brain metastases. During 1982–1994, most patients received
WBRT only as follows: WBRT only—14 (60.9%), surgical
resection, and WBRT—5 (21.7%), steroids only—4 (17.4%).
During 1995–2010, the therapeutic approach was more
aggressive; 50% of patients underwent surgical resection
and most patients received multimodal treatment with
adjuvant radiotherapy or chemotherapy as follows: surgery
and WBRT—3 (15%), surgery, WBRT and chemotherapy—
3 (15%), chemotherapy, and WBRT—3 (15%), surgery and
chemotherapy—3 (15%), WBRT alone—3 (15%), surgery
alone—1 (5%), chemotherapy alone—1 (5%), and steroids
only—3(15%).During1982–1994,themediansurvivalafter
diagnosisofbrainmetastaseswas5.0monthsonly,whereasit
was 17.6 months during 1995–2010 (P = 0.03). The authors
[56] concluded that an aggressive multimodal treatment
approach including surgical resection followed by radio-
therapy and/or chemotherapy might prolong the survival of
patients with brain metastases from ovarian carcinoma.
Although the experience of using SRS/GKRS in the
treatment of brain metastases from ovarian carcinoma is still
limited, it seems that SRS/GKRS will gain more popularity
in the future since patients with a limited number of brain
metastases may be treated with SRS/GKRS without WBRT.
Repeat SRS/GKRS may be performed for new lesions in the
brain to avoid or delay use of WBRT for as long as possible.
Therationale forthis approachis the avoidanceofsigniﬁcant
neurotoxicity from WBRT. Thus, patients treated with SRS
alone may experience fewer cognitive and constitutional side
eﬀects. In addition, there is an advantage for use of SRS in
treating patients with single brain metastases who are unable
to tolerate surgery and for those with surgically inaccessible
lesions. Kim et al. [53] have asserted that brain metastases
fromovariancarcinomaaregoodcandidatesforSRSbecause
of their spherical shape and, therefore, the role of SRS for
the treatment of brain metastases from ovarian carcinoma is
expected to increase.
6.Survival
The survival time after diagnosis of ovarian carcinoma was
available in 16 series totaling 236 patients [13, 20, 24, 26,
27, 29–31, 35, 38, 43, 45, 47, 49, 52, 55]( Table 1). The
medians of the survival times after diagnosis of ovarian
carcinoma ranged from 24 to 67 months with a median
of the medians of 33.3 months (Table 1). The survival
time after diagnosis of CNS metastases was available in 36
series totaling 513 patients [6, 13, 20–22, 24, 26–38, 40–56]
(Table 1).Themediansofthesurvivaltimesafterdiagnosisof
brain metastases ranged from 1 to 28 months with a median
of the medians of 6.4 months. Thus, overall, the survival
of patients after diagnosis of brain metastases from ovarian
carcinoma is poor. Nevertheless, the survival after diagnosis
ofbrainmetastasesisaﬀectedbythestatus(controlledversus
uncontrolled) and extent (cranial metastases only versus
cranial and extracranial metastases) of the primary disease
and by the number, volume, and site of metastases in the
brain parenchyma. In patients in whom multimodal therapy
containing craniotomy or SRS/GKRS is feasible, the use of
multimodal therapy containing craniotomy or SRS/GKRS
may increase considerably the survival after diagnosis of
brain metastases from ovarian carcinoma.
7. Conclusion
Brain metastasis from ovarian carcinoma is uncommon
with less than 600 cases documented in the literature. In
the prechemotherapy era, the incidence of brain metastasis
among living ovarian carcinoma patients was almost nil
because of the short survival of advanced-stage ovarianISRN Oncology 11
carcinoma patients that did not allow enough time for brain
metastasis to develop. With the advent of chemotherapy for
ovarian carcinoma, especially platinum-based chemother-
apy, a considerable lengthening in the survival of advanced-
stage ovarian carcinoma patients with a median of about
two years has been achieved. This prolonged survival has
allowed suﬃcient time for brain metastases to develop
and become apparent. Nevertheless, the notion expressed
by some authors that the incidence of brain metastasis
among ovarian carcinoma patients is continuing to rise in
the postchemotherapy era and even approaching >10% is
not supported by most series published in the literature
that show that the incidence of brain metastases among
ovarian carcinoma patients is usually within the range of
1–3%. The primary ovarian carcinoma metastasizing to
the brain is usually an advanced-stage (III/IV) and high-
grade (G3) epithelial serous carcinoma that was treated
primarily by cytoreductive (debulking) surgery followed
by adjuvant chemotherapy. Some of these patients had
after completion of ﬁrst-line chemotherapy a second-look
procedure which was often negative. The median interval
between diagnosis of ovarian carcinoma and detection of
brain metastasis is about two years. Most often, brain
metastase aﬀecting the cerebrum, are multiple and part of
a disseminated disease. The following variables aﬀect the
prognosis and guide treatment decisions in patients with
brain metastases from ovarian carcinoma: age, Karnofsky
performance status (KPS), state of control of the primary
disease, absence or presence of extracranial metastases, the
number,location,andvolumeofbrainmetastases,andmode
of therapy of brain metastases. Treatment of brain metastasis
has evolved over the years from WBRT only for most
patients to multimodal therapy including surgical resection,
if feasible, followed by WBRT and/or chemotherapy. The
median survival after diagnosis of brain metastases is about
6 months; nevertheless, a better survival is achieved with
multimodal therapy, if feasible, including surgical resection
than with WBRT alone. The experience of using SRS or
GKRS in the treatment of brain metastases from ovarian
carcinoma is still limited. Early detection of brain metastases
in ovarian carcinoma patients is of utmost importance since
brain metastases at their early stage of development in
the brain parenchyma are still of small volume and, thus,
much more feasible for surgical resection or SRS/GKRS
with less complications and better survival than metastases
at an advanced stage of their development in the brain.
Thus, it is suggested that brain imaging studies should be
included in the routine followup of patients after primary
treatment of ovarian carcinoma. Besides, the emergence of
o n eo fm o r en e u r o l o g i c a ls y m p t o m sa n ds i g n si na no v a r i a n
carcinoma patient should prompt an immediate search for
brain metastases with use of brain imaging studies.
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